Archer's Trading Company; Revocation of Registration, 42114-42118 [E7-14815]
Download as PDF
42114
Federal Register / Vol. 72, No. 147 / Wednesday, August 1, 2007 / Notices
relating to the Consent Decree.
Comments should be addressed to the
Assistant Attorney General of the
Environment and Natural Resources
Division, and either e-mailed to
pubcomment-ees.enrd@usdoj.gov, or
mailed to the, P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611, and should refer to United
States v. EPNG, D.J. Ref. 90–5–1–1–
08184.
The Consent Decree may be examined
at the Office of the United States
Attorney, Federal Office Building, 201
Third Street, NW., Suite 900,
Albuquerque, New Mexico 87102, and
at United States Department of
Transportation Docket Operations
facility, West Building, Room W–12–
140, 1200 New Jersey Avenue, SE.,
Washington, DC 20590. During the
public comment period, the Consent
Decree may also be examined on the
following Department of Justice, Web
site, https://www.usdoj.gov/enrd/
Consent_Decrees.html. A copy of the
Consent Decree may also be obtained by
mail from the Consent Decree Library,
P.O. Box 7611, U.S. Department of
Justice, Washington, DC 20044–7611 or
by faxing or e-mailing a request to Tonia
Fleetwood (tonia.fleetwood@usdoj.gov),
fax no. (202) 514–0097, phone
confirmation number (202) 514–1547. In
requesting a copy from the Consent
Decree Library, please enclose a check
in the amount of $28.00 (25 cents per
page reproduction cost) payable to the
U.S. Treasury or, if by e-mail or fax,
forward a check in that amount to the
Consent Decree Library at the stated
address.
Thomas Mariani,
Assistant Chief, Environmental Enforcement
Section, Environment and Natural Resource
Division.
[FR Doc. 07–3751 Filed 7–31–07; 8:45 am]
BILLING CODE 4410–15–M
DEPARTMENT OF JUSTICE
jlentini on PROD1PC65 with NOTICES
Notice of Lodging Proposed Consent
Decree
In accordance with Departmental
Policy, 28 C.F.R. 50.7, notice is hereby
given that a proposed consent decree in
United States v. Kenrock, Inc., John Doe,
and Frank Lisa, Case No. 3:05–CV–0057
AS, was lodge with the United States
District Court for the Northern District
of Indiana on July 23, 2007. This
proposed Consent Decree concerns a
complaint filed by the United States
against the Defendants pursuant to
Section 301(a) of the Clean Water Act
(‘‘CWA’’), 33 U.S.C. 1311(a), to obtain
injunctive relief from and impose civil
VerDate Aug<31>2005
20:12 Jul 31, 2007
Jkt 211001
penalties against the Defendants for
filling wetlands without a permit.
The proposed Consent Decree
resolves these allegations by requiring
the Defendants to restore the impacted
areas and to pay a civil penalty. The
Department of Justice will accept
written comments relating to this
proposed Consent Decree for thirty (30)
days from the date of publication of this
notice. Please address comments to
Clifford D. Johnson, Assistant United
States Attorney, 204 S. Main Street,
Room M–01, South Bend, Indiana 46601
and refer to United States of America v.
Kenrock, Inc., John Doe, and Frank Lisa,
Case No. 3:05–CV–0057 AS.
The proposed Consent Decree may be
examined at the Clerk’s Office, United
States District Court for the Northern
District of Indiana, South Bend
Division, 204 S. Main Street, South
Bend, IN 46601. In addition, the
proposed Consent Decree may be
viewed on the World Wide Web at
https://www.usdoj.gov/enrd/open.html.
Scott Schachter,
Assistant Chief, Environmental Defense
Section, Environment & Natural Resources
Division.
[FR Doc. 07–3748 Filed 7–31–07; 8:45 am]
BILLING CODE 4410–15–M
DEPARTMENT OF JUSTICE
Notice of Lodging of Consent Decree
Under the Oil Pollution Act (‘‘OPA’’)
Notice is hereby given that on July 20,
2007, a proposed Consent Decree in
United States v. Texmo Oil Company
Jobbers, Inc., Civil Action No. 2:07–cv–
01401–DKD (D. Ariz.), was lodged with
the United States District Court for the
District of Arizona. The proposed
Consent Decree resolves the United
States’ claim against Texmo Oil
Company Jobbers, Inc. (‘‘Texmo’’), for
natural resources damages under the Oil
Pollution Act, 33 U.S.C. Sections 2701–
2761, relating to a spill of approximately
7,700 gallons of diesel fuel into the Bill
Williams River National Wildlife Refuge
in Arizona. The Consent Decree requires
Texmo to pay to $1,217,382.91 to the
United States for damages for injuries to
natural resources that resulted from the
spill.
The Department of Justice will receive
for a period of thirty (30) days from the
date of this publication comments
relating to the proposed Consent Decree.
Comments should be addressed to the
Assistant Attorney General,
Environment and Natural Resources
Division, and either e-mailed to
pubcomment-ees.enrd@usdoj.gov or
mailed to P.O. Box 7611, U.S.
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
Department of Justice, Washington, DC
20044–7611, and should refer to United
States v. Texmo Oil Company Jobbers,
Inc., D.J. Ref. 90–5–1–1–09082.
The proposed Consent Decree may be
examined at the Office of the Solicitor,
Phoenix Field Office, U.S. Department
of the Interior, 401 W. Washington
Street SPC 44, Suite 404, Phoenix, AZ
85003–2151. During the public
comment period, the Consent Decree
may also be examined on the following
Department of Justice Web site, https://
www.usdoj.gov/enrd/
Consent_Decrees.html. A copy of the
proposed Consent Decree may also be
obtained by mail from the Consent
Decree Library, P.O. Box 7611, U.S.
Department of Justice, Washington, DC
20044–7611 or by faxing or e-mailing a
request to Tonia Fleetwood
(tonia.fleetwood@usdoj.gov), fax no.
(202) 514–0097, phone confirmation no.
(202) 514–1547. In requesting a copy
from the Consent Decree Library, please
enclose a check in the amount of $4.25
(25 cents per page reproduction cost)
payable to the ‘‘U.S. Treasury’’ or, if by
e-mail or fax, forward a check in that
amount to the Consent Decree Library at
the stated address.
Henry S. Friedman,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 07–3752 Filed 7–31–07; 8:45 am]
BILLING CODE 4410–15–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Archer’s Trading Company;
Revocation of Registration
On February 6, 2006, the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, issued an Order to
Show Cause to Archer’s Trading
Company (Respondent), of
Mechanicsville, Virginia. The Show
Cause Order proposed the revocation of
Respondent’s DEA Certificate of
Registration, 003001ATY, as a
distributor of List I chemicals, on the
ground that its ‘‘continued registration
is inconsistent with the public interest.’’
Show Cause Order at 1. The Show
Cause Order also proposed the denial of
any pending applications for renewal or
modification of Respondent’s
registration. Id.
The Show Cause Order specifically
alleged that Respondent distributed List
I chemicals to gas stations and
convenience stores, which DEA has
found are non-traditional retailers of
E:\FR\FM\01AUN1.SGM
01AUN1
Federal Register / Vol. 72, No. 147 / Wednesday, August 1, 2007 / Notices
jlentini on PROD1PC65 with NOTICES
these products for legitimate therapeutic
demand. Id. at 2–3. The Show Cause
Order alleged that during the period
2001 through 2003, Respondent ‘‘sold
over-threshold amounts of
pseudoephedrine to an unregistered
individual [who] was subsequently
convicted of the federal offense of
unlawful distribution of listed
chemicals.’’ Id. at 2. The Show Cause
Order also alleged that DEA
investigators audited Respondent’s
handling of List I chemical products and
found that it ‘‘was unable to account for
nearly 3,800 bottles of 60-count
combination ephedrine’’ products and
that there were ‘‘numerous
discrepancies in the firm’s sales
receipts.’’ Id.
The Show Cause Order further alleged
that ‘‘sometime in October–November
2004, [Respondent] moved its listed
chemicals to an unapproved location in
Ashland, Virginia.’’ Id. at 3. Relatedly,
the Show Cause Order alleged that
Respondent violated Federal law by
distributing products out of the Ashland
location. Id. The Show Cause Order also
alleged that Respondent had failed to
report a theft of listed chemicals that
had occurred at the Ashland location.
Id.
On February 13, 2006, the Show
Cause Order was served on
Respondent’s counsel by certified mail,
return receipt requested. On March 13,
2006, Respondent, through its counsel,
requested a hearing. The matter was
assigned to Administrative Law (ALJ)
Judge Mary Ellen Bittner. On November
2, 2006, however, Respondent
submitted a letter withdrawing its
request for a hearing and waiving its
right to a hearing. Accordingly, on
November 8, 2006, the ALJ terminated
the proceeding.
On or about June 11, 2007, the
investigative file was forwarded to me
for final agency action. Based on
Respondent’s letter waiving his right to
a hearing, I therefore enter this Final
Order without a hearing based on
relevant material contained in the
investigative file, see 21 CFR 1301.43(e),
and make the following findings.
Findings
Respondent is the holder of DEA
Certificate of Registration, 003001ATY,
which authorizes it to distribute the List
I chemicals pseudoephedrine,
ephedrine and phenylpropanolamine, at
the registered location of 10247
Finlandia Lane, Mechanicsville,
Virginia. The expiration date of
Respondent’s registration was June 30,
2004. On May 24, 2004, however,
Respondent submitted a renewal
application. I therefore find that
VerDate Aug<31>2005
20:12 Jul 31, 2007
Jkt 211001
Respondent’s registration has remained
in effect pending the issuance of this
Final Order. See 5 U.S.C. 558(c).
Both pseudoephedrine and ephedrine
currently have therapeutic uses. See,
e.g., Tri-County Bait Distributors, 71 FR
52160, 52161 (2006).1 Both chemicals
are, however, regulated under the
Controlled Substances Act because they
are precursor chemicals which are
easily extracted from non-prescription
products and used in the illicit
manufacture of methamphetamine, a
Schedule II controlled substance. See 21
U.S.C. 802(34); 21 CFR 1308.12(d).
Methamphetamine ‘‘is a powerful and
addictive central nervous system
stimulant.’’ T. Young Associates, Inc.,
71 FR 60567 (2006) (other citations
omitted). As noted in numerous DEA
final orders, the illegal manufacture and
abuse of methamphetamine pose a grave
threat to this country. See id.
Methamphetamine abuse has destroyed
numerous lives and families. Id.
Moreover, because of the toxic nature of
the chemicals used in making the drug,
illicit methamphetamine laboratories
cause serious environmental harms. Id.
Respondent is owned and operated by
Mr. Archer Carr Satterfield, Jr.
Respondent distributes dry goods,
cakes, pies, and over-the-counter
medicines (including those containing
listed chemicals) to gas stations,
convenience stores and small grocery
stores in central Virginia. List I
chemicals account for between 15 and
20 percent of Respondent’s business. As
of February 2004, the business was
located at Mr. Satterfield’s private
residence in Mechanicsville, Virginia.
On June 10, 2003, two DEA Diversion
Investigators (DIs) went to Respondent’s
registered location to conduct a
regulatory inspection. As part of the
inspection, the DIs conducted an audit
of Respondent’s handling of six
combination ephedrine products during
the period June 1, 2002, through June
10, 2003. Notwithstanding that the DIs
used zero as the initial inventory for
each of the audited products, they found
that Respondent had large shortages in
five of the products.
For example, with respect to the sixtycount bottles of Mini Thins, Respondent
was short 144,792 dosage units or 2413
bottles. As for the six-count packets of
Mini Thins, Respondent was short
12,660 dosage units or 2,110 packets.
FDA is, however, currently proposing to
remove combination ephedrine-guaifenesin
products from its over-the-counter (OTC) drug
monograph and to declare them not safe and
effective for OTC use. See 70 FR 40232 (2005).
While Respondent also sought authority to handle
phenylpropanolamine, there is no evidence in the
file that it actually handled the product.
PO 00000
1 The
Frm 00074
Fmt 4703
Sfmt 4703
42115
With respect to the sixty-count bottles
of Biotek Ephedrine, Respondent was
short 80,640 dosage units or 1344
bottles. As for the six-count packets of
Biotek Ephedrine, Respondent was short
8,856 dosage units or 1476 packets.
Because zero was used as the starting
inventory for each of the products (and
thus any product actually on hand on
the beginning date would not be
counted), the actual shortages were
likely greater than those calculated by
the DIs.
During the audit, the DIs also found
that a substantial number of
Respondent’s sale invoices were
incomplete. Some of the invoices lacked
the purchaser’s address information
including its street and city. Others
lacked information regarding the
quantity and product size.
During this inspection, Mr. Satterfield
told the DIs that he was suspicious of
the activities of one of his customer’s,
Fasil Mitha, the owner of Trio’s Market/
California Imports. Mr. Satterfield
further related that Mitha had told him
that he ‘‘sells to customers off the
shelf.’’ Upon reviewing Respondent’s
sales invoices, the DIs determined that
Respondent has sold nearly 47,000
dosage units of combination ephedrine
products to Mitha between November
20, 2002, and June 4, 2003. This would
amount to approximately 782 sixtycount bottles during a six-and-a-half
month period.2
During the audit period, Respondent
also sold large quantities to a store
identified as Market #14, in Richmond,
Virginia. More specifically, Respondent
sold this entity 50,554 dosage units
between August 13, 2002, and May 22,
2003. This would amount to
approximately 842 sixty-count bottles.
Sometime in either October or
November 2004, Mr. Satterfield notified
the DEA Richmond office that he had
moved his business from his residence
in Mechanicsville, Virginia, to a new
location at 11262 Elmont Road,
Ashland, Virginia. Mr. Satterfield
requested that DEA visit his new
location and approve his request for
modification.
As part of the process, Mr. Satterfield
was asked to provide a complete
customer list. Mr. Satterfield submitted
a customer list, but it was missing
address and phone number information
2 According to the investigative file, Mitha
subsequently pled guilty to violating 21 U.S.C.
§ 841(c)(2), which makes it a criminal offense to
knowingly ‘‘possess[ ] or distribute[ ] a listed
chemical knowing, or having reasonable cause to
believe, that the listed chemical will be used to
manufacture a controlled substance except as
authorized by’’ the CSA. Mitha was sentenced to
135 months in prison.
E:\FR\FM\01AUN1.SGM
01AUN1
42116
Federal Register / Vol. 72, No. 147 / Wednesday, August 1, 2007 / Notices
for nine of his customers. He also failed
to provide the address, phone number,
social security number and date of birth
for one of his employees.
The DIs instructed Mr. Satterfield that
he could not store listed chemicals at
his new location until his request for the
modification was approved. Mr.
Satterfield stated that he would keep his
List I products at his Mechanicsville
location.
Subsequently, in March 2005, the DIs
obtained an incident report from the
Hanover County Sheriff’s Department
pertaining to a theft that had occurred
at the Ashland property on the night of
November 1–2, 2004. According to the
report, at approximately midnight, Mr.
Satterfield had parked his delivery truck
at his Ashland property. When Mr.
Satterfield returned to the property the
following morning, both the truck and a
trailer that he stored merchandise in
had been broken into.
Mr. Satterfield reported that
approximately $4,609 in merchandise
had been stolen. Among the stolen items
were various OTC drug products
including listed chemical products. Mr.
Satterfield expressed to the responding
officer his concern for the consequences
were DEA to find out about the theft
because the products were not locked in
a secure place. Mr. Satterfield further
told the officer that he would never get
a license if DEA found out about the
theft. Mr. Satterfield did not report the
theft to this Agency.
On June 22, 2005, two DIs went to
Respondent’s Ashland facility. During
the visit, the DIs found that substantial
quantities of various List I chemical
products were stored in the building
and were on the delivery truck. Mr.
Satterfield told the DIs that the products
that were on the delivery truck were
going to be offloaded and stored in the
building that evening.
jlentini on PROD1PC65 with NOTICES
Discussion
Section 304(a) of the Controlled
Substances Act provides that a
registration to distribute a List I
chemical ‘‘may be suspended or revoked
* * * upon a finding that the registrant
* * * has committed such acts as
would render his registration under
section 823 of this title inconsistent
with the public interest as determined
under such section.’’ 21 U.S.C.
824(a)(4). In making this determination,
Congress directed that I consider the
following factors:
(1) Maintenance by the applicant of
effective controls against diversion of listed
chemicals into other than legitimate
channels;
(2) Compliance by the applicant with
applicable Federal, State, and local law;
VerDate Aug<31>2005
20:12 Jul 31, 2007
Jkt 211001
(3) Any prior conviction record of the
applicant under Federal or State laws relating
to controlled substances or to chemicals
controlled under Federal or State law;
(4) Any past experience of the applicant in
the manufacture and distribution of
chemicals; and
(5) Such other factors as are relevant to and
consistent with the public health and safety.
Id. § 823(h).
‘‘These factors are considered in the
disjunctive.’’ Joy’s Ideas, 70 FR 33195,
33197 (2005). I may rely on any one or
a combination of factors, and may give
each factor the weight I deem
appropriate in determining whether a
registration should be revoked or an
application for a renewal or
modification of a registration should be
denied. See, e.g., David M. Starr, 71 FR
39367, 39368 (2006); Energy Outlet, 64
FR 14269 (1999). Moreover, I am ‘‘not
required to make findings as to all of the
factors.’’ Hoxie v. DEA, 419 F.3d 477,
482 (6th Cir. 2005); Morall v. DEA, 412
F.3d 165, 173–74 (D.C. Cir. 2005). In
this case, I conclude that factors one,
two, four, and five establish that
Respondent’s continued registration
would be ‘‘inconsistent with the public
interest.’’ 21 U.S.C. 823(h). Accordingly,
Respondent’s registration will be
revoked and its pending applications for
renewal and modification of its
registration will be denied.
Factor One—Maintenance of Effective
Controls Against Diversion
Under DEA’s regulations, a List I
chemical distributor is required to
‘‘provide effective controls and
procedures to guard against theft and
diversion of List I chemicals.’’ 21 CFR
1309.71(a). The regulations further
provide that ‘‘[i]n evaluating the
effectiveness of security controls and
procedures, the Administrator shall
consider * * * [t]he adequacy of the
registrant’s or applicant’s systems for
monitoring the receipt, distribution, and
disposition of List I chemicals in its
operations.’’ Id. 1309.71(b)(8).
‘‘[M]aintaining proper records is
* * * an essential part of providing
effective controls against diversion.’’
John J. Fotinopoulos, 72 FR 24602,
24605 (2007). Here, the investigative file
establishes that many of Respondent’s
sales invoices were missing necessary
information for monitoring the
distribution and disposition of List I
products. More specifically,
Respondent’s invoices were frequently
missing critical information including
the street address and the city that its
customers were located in. Moreover,
the invoices also typically lacked
information regarding the size of the
List I products.
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
Beyond that, the accountability audit
found substantial shortages in five of the
List I products which Respondent
distributed. As found above,
Respondent was short 144,792 dosage
units or 2413 bottles of sixty-count
Mini-Thins; it was also short 12,660
dosage units or 2,110 six-count packets
of the product. Moreover, Respondent
was short 80,640 dosage units or 1344
sixty-count bottles of Biotek Ephedrine;
it was also short 8,856 dosage units or
1476 six-count packets of the product.
Finally, because the DIs assigned a
value of zero for the opening inventory
for each product, the actual amount of
the shortages may well have been even
larger.
Accordingly, I conclude that
Respondent does not maintain effective
controls against diversion and that this
finding provides reason alone to
conclude that its continued registration
‘‘is inconsistent with the public
interest.’’ 21 U.S.C. 823(h).
Factors Two and Four—Respondent’s
Compliance With Applicable Laws and
Its Experience in the Distribution of
Listed Chemicals
The investigative file also establishes
that Respondent failed to comply with
Federal law in two other respects. First,
Respondent clearly was distributing
listed chemical products out of its
Ashland facility which did not have a
registration. Second, Respondent failed
to report the November 2, 2004 theft of
listed chemical products as required by
21 U.S.C. 830(b)(1)(C).
Under Federal law, a registration is
location specific. See 21 U.S.C. 822(e)
(‘‘A separate registration shall be
required at each principal place of
business * * * where the applicant
* * * distributes * * * list I
chemicals.’’); see also 21 CFR
1309.23(a). Moreover, Federal law
clearly provides that a registrant is
‘‘authorized to possess [or] distribute’’ a
listed chemical only ‘‘to the extent
authorized by their registration and in
conformity with the other provisions of
this subchapter.’’ 21 U.S.C. 822(b).
Under DEA regulations, a request for
a modification is treated as a new
application. See 21 CFR 1309.61 (a
‘‘request for modification shall be
handled in the same manner as an
application for registration,’’ and, if
approved, ‘‘the Administrator shall
issue a new certificate of registration’’).
As I recently explained, a request for
modification does not authorize a
registrant to engage in listed chemical
activities at a new location until the
modification is approved and the new
certificate of registration is issued. See
Fotinopoulos, 72 FR at 24606. Cf.
E:\FR\FM\01AUN1.SGM
01AUN1
jlentini on PROD1PC65 with NOTICES
Federal Register / Vol. 72, No. 147 / Wednesday, August 1, 2007 / Notices
Orlando Wholesale, L.L.C., 71 FR 71555,
71557 (2006) (applicant’s change of
address following pre-registration
inspection renders application moot).
Here, Mr. Satterfield was specifically
told that he could not store listed
chemicals at the Ashland facility until
his request for modification was
approved. Moreover, Mr. Satterfield told
investigators that he would store
Respondent’s listed chemicals products
at his Mechanicsville location. Mr.
Satterfield nonetheless stored listed
chemicals at the Ashland facility both in
the building and in a truck which he
parked there and distributed listed
chemicals from this location. 21 U.S.C.
822(b) & (e). This violated Federal law.
Moreover, based on the date of the theft
(which occurred on November 2, 2004),
as well as the DIs’ finding that during
the June 22, 2005 visit, substantial
quantities of List I products were being
kept at the Ashland location, it appears
that Mr. Satterfield repeatedly violated
Federal law.
The evidence also establishes that
Respondent failed to report to DEA the
theft of listed chemicals that occurred
on November 2, 2004. Under 21 U.S.C.
830(b)(1)(C), a registrant must report
‘‘any unusual or excessive loss or
disappearance of a listed chemical
under the control of the regulated
person.’’
According to the responding officer,
Mr. Satterfield failed to report the theft
because he was concerned that if the
Agency found out, it would not grant
him a registration for his new location.
Mr. Satterfield thus not only violated
Federal law, making matters worse, he
did so intentionally.
Finally, the evidence establishes that
Respondent sold extraordinary
quantities of products to at least two
stores, and that the owner of one of the
stores, Mr. Mitha, subsequently plead
guilty to violating 21 U.S.C. 841(c)(2).
As found in T. Young Associates, 71 FR
at 60572, and numerous other cases,
non-traditional retailers (such as those
supplied by Respondent) sell only small
amounts of listed chemical products to
meet legitimate demand. On average,
these stores sell only $12.58 per month
of combination ephedrine products to
meet legitimate demand for these
products as a bronchodilator. Id.
The evidence establishes that in a sixand-a-half month period, Respondent
sold the equivalent of 782 sixty-count
bottles of combination-ephedrine
products to Mr. Mitha. While the record
does not establish the retail price Mr.
Mitha sold the products at, in other
cases DEA has found that smaller size
bottles ( 48 count ) sold for
approximately $5.99 to 6.99 each. See
VerDate Aug<31>2005
20:12 Jul 31, 2007
Jkt 211001
Wild West Wholesale, 72 FR 4042, 4043
(2007). Respondent’s sales to Mr.
Mitha’s store so exceeded legitimate
demand that it is clear that
Respondent’s products were diverted
into the illicit manufacture of
methamphetamine, a fact confirmed by
Mr. Mitha’s guilty plea.3 The same is
also true of Respondent’s sales to
Market #14.
Respondent’s violations of Federal
law and its experience in distributing
listed chemical products thus provide
further grounds to conclude that its
continued registration would be
‘‘inconsistent with the public interest.’’
21 U.S.C. 823(h).
Factor Five—Such Other Factors as Are
Relevant To and Consistent With Public
Health and Safety
The illicit manufacture and abuse of
methamphetamine have had pernicious
effects on families and communities
throughout the nation. Cutting off the
supply source of methamphetamine
traffickers is of critical importance in
protecting the American people from
the devastation wreaked by this drug.
While listed chemical products
containing pseudoephedrine and
ephedrine are currently recognized as
having legitimate medical uses, DEA
orders establish that convenience stores
and gas-stations constitute the nontraditional retail market for legitimate
consumers of products containing these
chemicals. See, e.g., Tri-County Bait
Distributors, 71 FR at 52161–62; D & S
Sales, 71 FR at 37609; Branex, Inc., 69
FR 8682, 8690–92 (2004). DEA has
further found that there is a substantial
risk of diversion of List I chemicals into
the illicit manufacture of
methamphetamine when these products
are sold by non-traditional retailers. See,
e.g., Joy’s Ideas, 70 FR at 33199 (finding
that the risk of diversion was ‘‘real’’ and
‘‘substantial’’); Jay Enterprises, Inc., 70
FR 24620, 24621 (2005) (noting
‘‘heightened risk of diversion’’ if
application to distribute to nontraditional retailers was granted).
3 Even if Mr. Satterfield lacked either actual or
constructive knowledge that Mr. Mitha was
diverting the products, his state of mind is
irrelevant. As I have previously noted, the public
interest standard does not require the Government
to ‘‘prove that a Registrant has acted with any
particular mens rea. Indeed, the diversion of List I
chemicals into the illicit manufacture of
methamphetamine poses the same threat to public
health and safety whether a registrant sells the
products knowing they will be diverted, sells them
with a reckless disregard for the diversion, or sells
them being totally unaware that the products were
being diverted.’’ T. Young, 71 FR at 60572 (footnote
omitted) (citing D & S Sales, 71 FR 37607, 37610–
12 (2006), and Joy’s Ideas, 70 FR 33195, 33198
(2005)).
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
42117
Accordingly, ‘‘[w]hile there are no
specific prohibitions under the
Controlled Substances Act regarding the
sale of listed chemical products to [gas
stations and convenience stores], DEA
has nevertheless found that [these
entities] constitute sources for the
diversion of listed chemical products.’’
Joey Enterprises, Inc., 70 FR 76866,
76867 (2005). See also TNT Distributors,
70 FR 12729, 12730 (2005) (special
agent testified that ‘‘80 to 90 percent of
ephedrine and pseudoephedrine being
used [in Tennessee] to manufacture
methamphetamine was being obtained
from convenience stores’’).4 The risk of
diversion is especially great where, as
here, a registrant cannot account for
large quantities of the products it
handles.
Moreover, the record establishes that
Respondent sold extraordinary
quantities of combination ephedrine
products to several stores including one
whose owner subsequently pled guilty
to distributing a listed chemical
knowing or having reasonable cause to
believe that the chemical would be used
to illegally manufacture a controlled
substance. See 21 U.S.C. 841(c)(2).
Thus, the record supports a finding that
Respondent’s products were diverted.
This factor thus provides additional
support for the conclusion that
Respondent’s continued registration ‘‘is
inconsistent with the public interest.’’
Id. § 823(h).
In sum, as found above under factor
one, the evidence supports a finding
that Respondent did not maintain
adequate records and an audit found
that it could not account for several
hundred thousand dosage units of
combination ephedrine products.
Moreover, while Respondent and its
owner have no record of relevant
criminal convictions, see 21 U.S.C.
823(h)(3), the evidence nonetheless
establishes that Respondent violated
federal law by: (1) Distributing listed
chemicals from a facility which was not
registered and likely did so for months,
and, (2) failing to report to DEA the theft
of listed chemicals from its nonapproved location. Finally, the evidence
supports a finding that a substantial
4 See OTC Distribution Co., 68 FR 70538, 70541
(2003) (noting ‘‘over 20 different seizures of [gray
market distributor’s] pseudoephedrine product at
clandestine sites,’’ and that in eight-month period
distributor’s product ‘‘was seized at clandestine
laboratories in eight states, with over 2 million
dosage units seized in Oklahoma alone.’’); MDI
Pharmaceuticals, 68 FR 4233, 4236 (2003) (finding
that ‘‘pseudoephedrine products distributed by
[gray market distributor] have been uncovered at
numerous clandestine methamphetamine settings
throughout the United States and/or discovered in
the possession of individuals apparently involved
in the illicit manufacture of methamphetamine’’).
E:\FR\FM\01AUN1.SGM
01AUN1
42118
Federal Register / Vol. 72, No. 147 / Wednesday, August 1, 2007 / Notices
portion of Respondent’s products were
diverted. Accordingly, I therefore
conclude that Respondent’s continued
registration ‘‘is inconsistent with the
public interest.’’ Id. § 823(h).
Order
Accordingly, pursuant to the
authority vested in me by 21 U.S.C.
823(h) & 824(a), as well as 28 CFR
0.100(b) & 0.104, I order that DEA
Certificate of Registration, 003001ATY,
issued to Archer’s Trading Company be,
and it hereby is, revoked. I further order
that Archer Trading Company’s pending
applications for modification and
renewal of its registration be, and they
hereby are, denied. This order is
effective August 31, 2007.
Dated: July 20, 2007.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E7–14815 Filed 7–31–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 05–33]
jlentini on PROD1PC65 with NOTICES
Holloway Distributing; Revocation of
Registration
On May 25, 2005, the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, issued an Order to
Show Cause to Holloway Distributing,
Inc. (Respondent), of Puxico, Missouri.
The Show Cause Order proposed the
revocation of Respondent’s DEA
Certificate of Registration, 003219HIY,
and the denial of Respondent’s pending
application for renewal of its
registration, on the ground that its
continued registration ‘‘is inconsistent
with the public interest.’’ Show Cause
Order at 1.
More specifically, the Show Cause
Order alleged that Respondent
distributed list I chemical products
containing pseudoephedrine, a
precursor chemical used in the illicit
manufacture of methamphetamine, a
schedule II controlled substance, to
convenience stores, gas stations, liquor
and video stores, and bait and tackle
shops in various parts of Missouri, the
State which has repeatedly ranked first
in the nation in the number of
clandestine methamphetamine lab
seizures. Id. at 2. The Show Cause Order
alleged that these establishments
constitute the non-traditional market for
consumers who purchase
pseudoephedrine products for
legitimate uses. Id. at 7. The Show
VerDate Aug<31>2005
20:12 Jul 31, 2007
Jkt 211001
Cause Order further alleged that
Respondent’s ‘‘sale of pseudoephedrine
products is inconsistent with the known
legitimate market and known end-user
demand for products of this type.’’ Id.
The Show Cause Order also alleged
that in March 2004, DEA investigators
conducted verifications of several
entities which Respondent identified as
its customers. Id. at 3–4. According to
the allegations, DEA investigators
determined that several of Respondent’s
customers were purchasing additional
list I chemical products from other
distributors and also selling other
products such as starting fluid and
lantern fuel which are used in the illicit
manufacture of methamphetamine. Id.
The Show Cause Order next alleged
that in March 2004, as part of a
regulatory investigation of Respondent,
DEA investigators conducted an
accountability audit of five list I
chemical products. Id. at 5. The Show
Cause Order alleged that there were
either overages or shortages for each
product, and that DEA investigators
found that Respondent had ‘‘failed to
notify the agency of a significant loss of
List I chemical products as required by
21 U.S.C. 830(b)(1)(C) and 21 CFR
1310.05(a)(3).’’ Id.
Finally, the Show Cause Order alleged
that between November 7, 2003, and
April 1, 2004, Respondent sold
pseudoephedrine products on numerous
occasions to one Keith Frankum,
notwithstanding that Frankum had
presented a sales tax exempt certificate
which indicated that his business
address was a local storage facility and
was vague when asked about the nature
of his business. Id. at 5–6. According to
the allegations, notwithstanding that
local law enforcement authorities had
told one of Respondent’s employees that
Frankum’s brother was ‘‘a meth cook,’’
and that its employees ‘‘referred to
[Frankum] as ‘the drug guy’ whenever
he arrived at Holloway to make a
purchase,’’ Respondent made additional
sales of pseudoephedrine products to
him. Id. at 6. The Show Cause Order
further alleged that in early April 2004,
Frankum was arrested and during a
search incident to the arrest, was found
to be in possession of twenty boxes of
pseudoephedrine products sold by
Respondent, an invoice from
Respondent, and a handwritten note
which read: ‘‘Be careful when leaving
here!’’ Id. at 5. According to the
allegations, Frankum subsequently told
DEA investigators that he sold
pseudoephedrine ‘‘to several repeat
customers’’ and that it ‘‘was a big seller
because it was used to make drugs.’’ Id.
at 6. The Show Cause Order also alleged
that Frankum admitted that he had a
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
prior arrest for possession of
methamphetamine and that he had done
‘‘a lot of meth’’ five years earlier. Id. The
Show Cause Order further alleged that
Respondent never reported to DEA its
sales to Frankum. Id. at 5.
On June 24, 2005, Respondent,
through its counsel, requested a hearing.
The matter was assigned to
Administrative Law Judge (ALJ) Gail A.
Randall, who conducted a hearing in
Arlington, Virginia, on February 7,
2006, and in Cape Girardeau, Missouri,
on February 22–23, 2006. During the
hearing, both parties called witnesses to
testify and introduced documentary
evidence. Following the hearing, both
parties submitted briefs containing
proposed findings of fact, conclusions of
law and argument.
On December 19, 2006, the ALJ
submitted her recommended decision
(hereinafter, ALJ). In her decision, the
ALJ concluded that the Government had
‘‘initially * * * met its burden of proof
* * * by demonstrating that the
Respondent made ‘grossly excessive
sales’ of listed chemical products
between October 1, 2003, and March 23,
2004.’’ ALJ at 40 (citing FOF 26). The
ALJ also acknowledged DEA precedent
holding that a registrant’s grossly
excessive sales support a finding that its
products were diverted and that its
continued registration would be
inconsistent with the public interest. Id.
at 40–41.
The ALJ concluded, however, that
Respondent’s continued registration
would not be inconsistent with the
public interest for two reasons. Id. at 41.
First, the ALJ noted that Respondent
had ‘‘demonstrated its willingness and
its ability to develop and implement
changes in its business processes
consistent with the [agency’s]
recommendations.’’ Id. Second, the ALJ
relied on Missouri’s recently enacted
restrictions on pseudoephedrine sales.
According to the ALJ, the statute
showed that ‘‘the State will be
monitoring the gelcap and liquid
pseudoephedrine products, if any,
found in the methamphetamine labs,’’
and that ‘‘[s]uch heightened scrutiny
leads to the conclusion that, if the
products of the Respondent, as well as
other distributors of List I chemical
products in Missouri, are found in illicit
methamphetamine laboratories, the
State will close the legislative loophole
afforded these limited products.’’ Id.
The ALJ reasoned that ‘‘[u]ntil such
time as the problem is substantiated
* * * the possibility of * * *
Respondent’s products being diverted
[should] not be relied upon to revoke’’
its registration. Id. The ALJ therefore
recommended that I not revoke
E:\FR\FM\01AUN1.SGM
01AUN1
Agencies
[Federal Register Volume 72, Number 147 (Wednesday, August 1, 2007)]
[Notices]
[Pages 42114-42118]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-14815]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Archer's Trading Company; Revocation of Registration
On February 6, 2006, the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, issued an Order to
Show Cause to Archer's Trading Company (Respondent), of Mechanicsville,
Virginia. The Show Cause Order proposed the revocation of Respondent's
DEA Certificate of Registration, 003001ATY, as a distributor of List I
chemicals, on the ground that its ``continued registration is
inconsistent with the public interest.'' Show Cause Order at 1. The
Show Cause Order also proposed the denial of any pending applications
for renewal or modification of Respondent's registration. Id.
The Show Cause Order specifically alleged that Respondent
distributed List I chemicals to gas stations and convenience stores,
which DEA has found are non-traditional retailers of
[[Page 42115]]
these products for legitimate therapeutic demand. Id. at 2-3. The Show
Cause Order alleged that during the period 2001 through 2003,
Respondent ``sold over-threshold amounts of pseudoephedrine to an
unregistered individual [who] was subsequently convicted of the federal
offense of unlawful distribution of listed chemicals.'' Id. at 2. The
Show Cause Order also alleged that DEA investigators audited
Respondent's handling of List I chemical products and found that it
``was unable to account for nearly 3,800 bottles of 60-count
combination ephedrine'' products and that there were ``numerous
discrepancies in the firm's sales receipts.'' Id.
The Show Cause Order further alleged that ``sometime in October-
November 2004, [Respondent] moved its listed chemicals to an unapproved
location in Ashland, Virginia.'' Id. at 3. Relatedly, the Show Cause
Order alleged that Respondent violated Federal law by distributing
products out of the Ashland location. Id. The Show Cause Order also
alleged that Respondent had failed to report a theft of listed
chemicals that had occurred at the Ashland location. Id.
On February 13, 2006, the Show Cause Order was served on
Respondent's counsel by certified mail, return receipt requested. On
March 13, 2006, Respondent, through its counsel, requested a hearing.
The matter was assigned to Administrative Law (ALJ) Judge Mary Ellen
Bittner. On November 2, 2006, however, Respondent submitted a letter
withdrawing its request for a hearing and waiving its right to a
hearing. Accordingly, on November 8, 2006, the ALJ terminated the
proceeding.
On or about June 11, 2007, the investigative file was forwarded to
me for final agency action. Based on Respondent's letter waiving his
right to a hearing, I therefore enter this Final Order without a
hearing based on relevant material contained in the investigative file,
see 21 CFR 1301.43(e), and make the following findings.
Findings
Respondent is the holder of DEA Certificate of Registration,
003001ATY, which authorizes it to distribute the List I chemicals
pseudoephedrine, ephedrine and phenylpropanolamine, at the registered
location of 10247 Finlandia Lane, Mechanicsville, Virginia. The
expiration date of Respondent's registration was June 30, 2004. On May
24, 2004, however, Respondent submitted a renewal application. I
therefore find that Respondent's registration has remained in effect
pending the issuance of this Final Order. See 5 U.S.C. 558(c).
Both pseudoephedrine and ephedrine currently have therapeutic uses.
See, e.g., Tri-County Bait Distributors, 71 FR 52160, 52161 (2006).\1\
Both chemicals are, however, regulated under the Controlled Substances
Act because they are precursor chemicals which are easily extracted
from non-prescription products and used in the illicit manufacture of
methamphetamine, a Schedule II controlled substance. See 21 U.S.C.
802(34); 21 CFR 1308.12(d).
---------------------------------------------------------------------------
\1\ The FDA is, however, currently proposing to remove
combination ephedrine-guaifenesin products from its over-the-counter
(OTC) drug monograph and to declare them not safe and effective for
OTC use. See 70 FR 40232 (2005). While Respondent also sought
authority to handle phenylpropanolamine, there is no evidence in the
file that it actually handled the product.
---------------------------------------------------------------------------
Methamphetamine ``is a powerful and addictive central nervous
system stimulant.'' T. Young Associates, Inc., 71 FR 60567 (2006)
(other citations omitted). As noted in numerous DEA final orders, the
illegal manufacture and abuse of methamphetamine pose a grave threat to
this country. See id. Methamphetamine abuse has destroyed numerous
lives and families. Id. Moreover, because of the toxic nature of the
chemicals used in making the drug, illicit methamphetamine laboratories
cause serious environmental harms. Id.
Respondent is owned and operated by Mr. Archer Carr Satterfield,
Jr. Respondent distributes dry goods, cakes, pies, and over-the-counter
medicines (including those containing listed chemicals) to gas
stations, convenience stores and small grocery stores in central
Virginia. List I chemicals account for between 15 and 20 percent of
Respondent's business. As of February 2004, the business was located at
Mr. Satterfield's private residence in Mechanicsville, Virginia.
On June 10, 2003, two DEA Diversion Investigators (DIs) went to
Respondent's registered location to conduct a regulatory inspection. As
part of the inspection, the DIs conducted an audit of Respondent's
handling of six combination ephedrine products during the period June
1, 2002, through June 10, 2003. Notwithstanding that the DIs used zero
as the initial inventory for each of the audited products, they found
that Respondent had large shortages in five of the products.
For example, with respect to the sixty-count bottles of Mini Thins,
Respondent was short 144,792 dosage units or 2413 bottles. As for the
six-count packets of Mini Thins, Respondent was short 12,660 dosage
units or 2,110 packets.
With respect to the sixty-count bottles of Biotek Ephedrine,
Respondent was short 80,640 dosage units or 1344 bottles. As for the
six-count packets of Biotek Ephedrine, Respondent was short 8,856
dosage units or 1476 packets. Because zero was used as the starting
inventory for each of the products (and thus any product actually on
hand on the beginning date would not be counted), the actual shortages
were likely greater than those calculated by the DIs.
During the audit, the DIs also found that a substantial number of
Respondent's sale invoices were incomplete. Some of the invoices lacked
the purchaser's address information including its street and city.
Others lacked information regarding the quantity and product size.
During this inspection, Mr. Satterfield told the DIs that he was
suspicious of the activities of one of his customer's, Fasil Mitha, the
owner of Trio's Market/California Imports. Mr. Satterfield further
related that Mitha had told him that he ``sells to customers off the
shelf.'' Upon reviewing Respondent's sales invoices, the DIs determined
that Respondent has sold nearly 47,000 dosage units of combination
ephedrine products to Mitha between November 20, 2002, and June 4,
2003. This would amount to approximately 782 sixty-count bottles during
a six-and-a-half month period.\2\
---------------------------------------------------------------------------
\2\ According to the investigative file, Mitha subsequently pled
guilty to violating 21 U.S.C. Sec. 841(c)(2), which makes it a
criminal offense to knowingly ``possess[ ] or distribute[ ] a listed
chemical knowing, or having reasonable cause to believe, that the
listed chemical will be used to manufacture a controlled substance
except as authorized by'' the CSA. Mitha was sentenced to 135 months
in prison.
---------------------------------------------------------------------------
During the audit period, Respondent also sold large quantities to a
store identified as Market 14, in Richmond, Virginia. More
specifically, Respondent sold this entity 50,554 dosage units between
August 13, 2002, and May 22, 2003. This would amount to approximately
842 sixty-count bottles.
Sometime in either October or November 2004, Mr. Satterfield
notified the DEA Richmond office that he had moved his business from
his residence in Mechanicsville, Virginia, to a new location at 11262
Elmont Road, Ashland, Virginia. Mr. Satterfield requested that DEA
visit his new location and approve his request for modification.
As part of the process, Mr. Satterfield was asked to provide a
complete customer list. Mr. Satterfield submitted a customer list, but
it was missing address and phone number information
[[Page 42116]]
for nine of his customers. He also failed to provide the address, phone
number, social security number and date of birth for one of his
employees.
The DIs instructed Mr. Satterfield that he could not store listed
chemicals at his new location until his request for the modification
was approved. Mr. Satterfield stated that he would keep his List I
products at his Mechanicsville location.
Subsequently, in March 2005, the DIs obtained an incident report
from the Hanover County Sheriff's Department pertaining to a theft that
had occurred at the Ashland property on the night of November 1-2,
2004. According to the report, at approximately midnight, Mr.
Satterfield had parked his delivery truck at his Ashland property. When
Mr. Satterfield returned to the property the following morning, both
the truck and a trailer that he stored merchandise in had been broken
into.
Mr. Satterfield reported that approximately $4,609 in merchandise
had been stolen. Among the stolen items were various OTC drug products
including listed chemical products. Mr. Satterfield expressed to the
responding officer his concern for the consequences were DEA to find
out about the theft because the products were not locked in a secure
place. Mr. Satterfield further told the officer that he would never get
a license if DEA found out about the theft. Mr. Satterfield did not
report the theft to this Agency.
On June 22, 2005, two DIs went to Respondent's Ashland facility.
During the visit, the DIs found that substantial quantities of various
List I chemical products were stored in the building and were on the
delivery truck. Mr. Satterfield told the DIs that the products that
were on the delivery truck were going to be offloaded and stored in the
building that evening.
Discussion
Section 304(a) of the Controlled Substances Act provides that a
registration to distribute a List I chemical ``may be suspended or
revoked * * * upon a finding that the registrant * * * has committed
such acts as would render his registration under section 823 of this
title inconsistent with the public interest as determined under such
section.'' 21 U.S.C. 824(a)(4). In making this determination, Congress
directed that I consider the following factors:
(1) Maintenance by the applicant of effective controls against
diversion of listed chemicals into other than legitimate channels;
(2) Compliance by the applicant with applicable Federal, State,
and local law;
(3) Any prior conviction record of the applicant under Federal
or State laws relating to controlled substances or to chemicals
controlled under Federal or State law;
(4) Any past experience of the applicant in the manufacture and
distribution of chemicals; and
(5) Such other factors as are relevant to and consistent with
the public health and safety.
Id. Sec. 823(h).
``These factors are considered in the disjunctive.'' Joy's Ideas,
70 FR 33195, 33197 (2005). I may rely on any one or a combination of
factors, and may give each factor the weight I deem appropriate in
determining whether a registration should be revoked or an application
for a renewal or modification of a registration should be denied. See,
e.g., David M. Starr, 71 FR 39367, 39368 (2006); Energy Outlet, 64 FR
14269 (1999). Moreover, I am ``not required to make findings as to all
of the factors.'' Hoxie v. DEA, 419 F.3d 477, 482 (6th Cir. 2005);
Morall v. DEA, 412 F.3d 165, 173-74 (D.C. Cir. 2005). In this case, I
conclude that factors one, two, four, and five establish that
Respondent's continued registration would be ``inconsistent with the
public interest.'' 21 U.S.C. 823(h). Accordingly, Respondent's
registration will be revoked and its pending applications for renewal
and modification of its registration will be denied.
Factor One--Maintenance of Effective Controls Against Diversion
Under DEA's regulations, a List I chemical distributor is required
to ``provide effective controls and procedures to guard against theft
and diversion of List I chemicals.'' 21 CFR 1309.71(a). The regulations
further provide that ``[i]n evaluating the effectiveness of security
controls and procedures, the Administrator shall consider * * * [t]he
adequacy of the registrant's or applicant's systems for monitoring the
receipt, distribution, and disposition of List I chemicals in its
operations.'' Id. 1309.71(b)(8).
``[M]aintaining proper records is * * * an essential part of
providing effective controls against diversion.'' John J. Fotinopoulos,
72 FR 24602, 24605 (2007). Here, the investigative file establishes
that many of Respondent's sales invoices were missing necessary
information for monitoring the distribution and disposition of List I
products. More specifically, Respondent's invoices were frequently
missing critical information including the street address and the city
that its customers were located in. Moreover, the invoices also
typically lacked information regarding the size of the List I products.
Beyond that, the accountability audit found substantial shortages
in five of the List I products which Respondent distributed. As found
above, Respondent was short 144,792 dosage units or 2413 bottles of
sixty-count Mini-Thins; it was also short 12,660 dosage units or 2,110
six-count packets of the product. Moreover, Respondent was short 80,640
dosage units or 1344 sixty-count bottles of Biotek Ephedrine; it was
also short 8,856 dosage units or 1476 six-count packets of the product.
Finally, because the DIs assigned a value of zero for the opening
inventory for each product, the actual amount of the shortages may well
have been even larger.
Accordingly, I conclude that Respondent does not maintain effective
controls against diversion and that this finding provides reason alone
to conclude that its continued registration ``is inconsistent with the
public interest.'' 21 U.S.C. 823(h).
Factors Two and Four--Respondent's Compliance With Applicable Laws and
Its Experience in the Distribution of Listed Chemicals
The investigative file also establishes that Respondent failed to
comply with Federal law in two other respects. First, Respondent
clearly was distributing listed chemical products out of its Ashland
facility which did not have a registration. Second, Respondent failed
to report the November 2, 2004 theft of listed chemical products as
required by 21 U.S.C. 830(b)(1)(C).
Under Federal law, a registration is location specific. See 21
U.S.C. 822(e) (``A separate registration shall be required at each
principal place of business * * * where the applicant * * * distributes
* * * list I chemicals.''); see also 21 CFR 1309.23(a). Moreover,
Federal law clearly provides that a registrant is ``authorized to
possess [or] distribute'' a listed chemical only ``to the extent
authorized by their registration and in conformity with the other
provisions of this subchapter.'' 21 U.S.C. 822(b).
Under DEA regulations, a request for a modification is treated as a
new application. See 21 CFR 1309.61 (a ``request for modification shall
be handled in the same manner as an application for registration,''
and, if approved, ``the Administrator shall issue a new certificate of
registration''). As I recently explained, a request for modification
does not authorize a registrant to engage in listed chemical activities
at a new location until the modification is approved and the new
certificate of registration is issued. See Fotinopoulos, 72 FR at
24606. Cf.
[[Page 42117]]
Orlando Wholesale, L.L.C., 71 FR 71555, 71557 (2006) (applicant's
change of address following pre-registration inspection renders
application moot).
Here, Mr. Satterfield was specifically told that he could not store
listed chemicals at the Ashland facility until his request for
modification was approved. Moreover, Mr. Satterfield told investigators
that he would store Respondent's listed chemicals products at his
Mechanicsville location. Mr. Satterfield nonetheless stored listed
chemicals at the Ashland facility both in the building and in a truck
which he parked there and distributed listed chemicals from this
location. 21 U.S.C. 822(b) & (e). This violated Federal law. Moreover,
based on the date of the theft (which occurred on November 2, 2004), as
well as the DIs' finding that during the June 22, 2005 visit,
substantial quantities of List I products were being kept at the
Ashland location, it appears that Mr. Satterfield repeatedly violated
Federal law.
The evidence also establishes that Respondent failed to report to
DEA the theft of listed chemicals that occurred on November 2, 2004.
Under 21 U.S.C. 830(b)(1)(C), a registrant must report ``any unusual or
excessive loss or disappearance of a listed chemical under the control
of the regulated person.''
According to the responding officer, Mr. Satterfield failed to
report the theft because he was concerned that if the Agency found out,
it would not grant him a registration for his new location. Mr.
Satterfield thus not only violated Federal law, making matters worse,
he did so intentionally.
Finally, the evidence establishes that Respondent sold
extraordinary quantities of products to at least two stores, and that
the owner of one of the stores, Mr. Mitha, subsequently plead guilty to
violating 21 U.S.C. 841(c)(2). As found in T. Young Associates, 71 FR
at 60572, and numerous other cases, non-traditional retailers (such as
those supplied by Respondent) sell only small amounts of listed
chemical products to meet legitimate demand. On average, these stores
sell only $12.58 per month of combination ephedrine products to meet
legitimate demand for these products as a bronchodilator. Id.
The evidence establishes that in a six-and-a-half month period,
Respondent sold the equivalent of 782 sixty-count bottles of
combination-ephedrine products to Mr. Mitha. While the record does not
establish the retail price Mr. Mitha sold the products at, in other
cases DEA has found that smaller size bottles ( 48 count ) sold for
approximately $5.99 to 6.99 each. See Wild West Wholesale, 72 FR 4042,
4043 (2007). Respondent's sales to Mr. Mitha's store so exceeded
legitimate demand that it is clear that Respondent's products were
diverted into the illicit manufacture of methamphetamine, a fact
confirmed by Mr. Mitha's guilty plea.\3\ The same is also true of
Respondent's sales to Market 14.
---------------------------------------------------------------------------
\3\ Even if Mr. Satterfield lacked either actual or constructive
knowledge that Mr. Mitha was diverting the products, his state of
mind is irrelevant. As I have previously noted, the public interest
standard does not require the Government to ``prove that a
Registrant has acted with any particular mens rea. Indeed, the
diversion of List I chemicals into the illicit manufacture of
methamphetamine poses the same threat to public health and safety
whether a registrant sells the products knowing they will be
diverted, sells them with a reckless disregard for the diversion, or
sells them being totally unaware that the products were being
diverted.'' T. Young, 71 FR at 60572 (footnote omitted) (citing D &
S Sales, 71 FR 37607, 37610-12 (2006), and Joy's Ideas, 70 FR 33195,
33198 (2005)).
---------------------------------------------------------------------------
Respondent's violations of Federal law and its experience in
distributing listed chemical products thus provide further grounds to
conclude that its continued registration would be ``inconsistent with
the public interest.'' 21 U.S.C. 823(h).
Factor Five--Such Other Factors as Are Relevant To and Consistent With
Public Health and Safety
The illicit manufacture and abuse of methamphetamine have had
pernicious effects on families and communities throughout the nation.
Cutting off the supply source of methamphetamine traffickers is of
critical importance in protecting the American people from the
devastation wreaked by this drug.
While listed chemical products containing pseudoephedrine and
ephedrine are currently recognized as having legitimate medical uses,
DEA orders establish that convenience stores and gas-stations
constitute the non-traditional retail market for legitimate consumers
of products containing these chemicals. See, e.g., Tri-County Bait
Distributors, 71 FR at 52161-62; D & S Sales, 71 FR at 37609; Branex,
Inc., 69 FR 8682, 8690-92 (2004). DEA has further found that there is a
substantial risk of diversion of List I chemicals into the illicit
manufacture of methamphetamine when these products are sold by non-
traditional retailers. See, e.g., Joy's Ideas, 70 FR at 33199 (finding
that the risk of diversion was ``real'' and ``substantial''); Jay
Enterprises, Inc., 70 FR 24620, 24621 (2005) (noting ``heightened risk
of diversion'' if application to distribute to non-traditional
retailers was granted).
Accordingly, ``[w]hile there are no specific prohibitions under the
Controlled Substances Act regarding the sale of listed chemical
products to [gas stations and convenience stores], DEA has nevertheless
found that [these entities] constitute sources for the diversion of
listed chemical products.'' Joey Enterprises, Inc., 70 FR 76866, 76867
(2005). See also TNT Distributors, 70 FR 12729, 12730 (2005) (special
agent testified that ``80 to 90 percent of ephedrine and
pseudoephedrine being used [in Tennessee] to manufacture
methamphetamine was being obtained from convenience stores'').\4\ The
risk of diversion is especially great where, as here, a registrant
cannot account for large quantities of the products it handles.
---------------------------------------------------------------------------
\4\ See OTC Distribution Co., 68 FR 70538, 70541 (2003) (noting
``over 20 different seizures of [gray market distributor's]
pseudoephedrine product at clandestine sites,'' and that in eight-
month period distributor's product ``was seized at clandestine
laboratories in eight states, with over 2 million dosage units
seized in Oklahoma alone.''); MDI Pharmaceuticals, 68 FR 4233, 4236
(2003) (finding that ``pseudoephedrine products distributed by [gray
market distributor] have been uncovered at numerous clandestine
methamphetamine settings throughout the United States and/or
discovered in the possession of individuals apparently involved in
the illicit manufacture of methamphetamine'').
---------------------------------------------------------------------------
Moreover, the record establishes that Respondent sold extraordinary
quantities of combination ephedrine products to several stores
including one whose owner subsequently pled guilty to distributing a
listed chemical knowing or having reasonable cause to believe that the
chemical would be used to illegally manufacture a controlled substance.
See 21 U.S.C. 841(c)(2). Thus, the record supports a finding that
Respondent's products were diverted. This factor thus provides
additional support for the conclusion that Respondent's continued
registration ``is inconsistent with the public interest.'' Id. Sec.
823(h).
In sum, as found above under factor one, the evidence supports a
finding that Respondent did not maintain adequate records and an audit
found that it could not account for several hundred thousand dosage
units of combination ephedrine products. Moreover, while Respondent and
its owner have no record of relevant criminal convictions, see 21
U.S.C. 823(h)(3), the evidence nonetheless establishes that Respondent
violated federal law by: (1) Distributing listed chemicals from a
facility which was not registered and likely did so for months, and,
(2) failing to report to DEA the theft of listed chemicals from its
non-approved location. Finally, the evidence supports a finding that a
substantial
[[Page 42118]]
portion of Respondent's products were diverted. Accordingly, I
therefore conclude that Respondent's continued registration ``is
inconsistent with the public interest.'' Id. Sec. 823(h).
Order
Accordingly, pursuant to the authority vested in me by 21 U.S.C.
823(h) & 824(a), as well as 28 CFR 0.100(b) & 0.104, I order that DEA
Certificate of Registration, 003001ATY, issued to Archer's Trading
Company be, and it hereby is, revoked. I further order that Archer
Trading Company's pending applications for modification and renewal of
its registration be, and they hereby are, denied. This order is
effective August 31, 2007.
Dated: July 20, 2007.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E7-14815 Filed 7-31-07; 8:45 am]
BILLING CODE 4410-09-P